
Summit Therapeutics (SMMT) Stock Forecast & Price Target
Summit Therapeutics (SMMT) Analyst Ratings
Bulls say
Summit Therapeutics Inc. exhibits a promising outlook based on the favorable early data from its HARMONi trial, where approximately 65% of participating patients have demonstrated a progression-free survival benefit, suggesting strong efficacy potential for its product candidate, ridinilazole. Additionally, positive projections for the ongoing Phase 3 trials in non-small cell lung cancer (NSCLC) further bolster confidence, with an anticipated significant improvement in overall survival metrics and a possible translation of progression-free survival benefits into a 30%-50% enhancement in median overall survival. The company's strategic positioning within an evolving market, where successful outcomes could lead to substantial revenue potential, reflects a robust growth trajectory, drawing parallels to established players like KEYTRUDA.
Bears say
The financial outlook for Summit Therapeutics Inc is negatively impacted by a bear case scenario that suggests a marginal clinical efficacy or new safety signals emerging in the Phase 3 study, which could significantly lower the probability of success for its product candidate, Ivo, to just 20%. Additionally, the company faces substantial risks, including a lack of differentiated clinical data and potential competitive drug approvals, which may hinder the sales potential of its products. Furthermore, there are concerns regarding regulatory risks, delays in development, clinical trial failures, and potential medium-term dilution risks that collectively contribute to an estimated net loss of $0.32 per share.
This aggregate rating is based on analysts' research of Summit Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Summit Therapeutics (SMMT) Analyst Forecast & Price Prediction
Start investing in Summit Therapeutics (SMMT)
Order type
Buy in
Order amount
Est. shares
0 shares